-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Nkarta (NASDAQ:NKTX) Downgraded by Oppenheimer
Nkarta (NASDAQ:NKTX) Downgraded by Oppenheimer
Oppenheimer downgraded shares of Nkarta (NASDAQ:NKTX – Get Rating) from an outperform rating to a market perform rating in a research note released on Thursday morning, Marketbeat reports.
A number of other research analysts have also weighed in on NKTX. Cantor Fitzgerald reaffirmed an overweight rating on shares of Nkarta in a research note on Wednesday, September 21st. Canaccord Genuity Group began coverage on shares of Nkarta in a report on Monday, October 10th. They issued a buy rating and a $25.00 price objective on the stock. Mizuho lowered their price objective on shares of Nkarta from $81.00 to $26.00 and set a buy rating on the stock in a report on Wednesday, November 16th. Finally, Canaccord Genuity Group began coverage on shares of Nkarta in a report on Monday, October 10th. They issued a buy rating and a $25.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $29.90.
Get Nkarta alerts:Nkarta Stock Performance
Shares of NKTX opened at $5.54 on Thursday. Nkarta has a twelve month low of $5.22 and a twelve month high of $20.35. The firm's 50 day moving average price is $9.73 and its two-hundred day moving average price is $12.45. The firm has a market cap of $270.41 million, a P/E ratio of -2.07 and a beta of -0.06.
Insider Buying and Selling
In other Nkarta news, CEO Paul J. Hastings sold 23,376 shares of Nkarta stock in a transaction on Wednesday, September 28th. The shares were sold at an average price of $13.03, for a total transaction of $304,589.28. Following the completion of the transaction, the chief executive officer now directly owns 250,959 shares of the company's stock, valued at $3,269,995.77. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 5.60% of the stock is owned by corporate insiders.Hedge Funds Weigh In On Nkarta
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NKTX. Parkwood LLC bought a new stake in shares of Nkarta in the second quarter valued at about $31,000. Quantbot Technologies LP boosted its position in shares of Nkarta by 39.1% in the first quarter. Quantbot Technologies LP now owns 3,200 shares of the company's stock valued at $36,000 after acquiring an additional 900 shares during the period. Denali Advisors LLC bought a new stake in shares of Nkarta in the second quarter valued at about $38,000. Point72 Hong Kong Ltd bought a new stake in shares of Nkarta in the third quarter valued at about $46,000. Finally, Federated Hermes Inc. boosted its position in shares of Nkarta by 735.3% in the first quarter. Federated Hermes Inc. now owns 4,711 shares of the company's stock valued at $54,000 after acquiring an additional 4,147 shares during the period. 87.22% of the stock is owned by institutional investors.
About Nkarta
(Get Rating)
Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
Read More
- Get a free copy of the StockNews.com research report on Nkarta (NKTX)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.
Oppenheimer downgraded shares of Nkarta (NASDAQ:NKTX – Get Rating) from an outperform rating to a market perform rating in a research note released on Thursday morning, Marketbeat reports.
据Marketbeat报道,在周四上午发布的一份研究报告中,奥本海默将恩卡塔(纳斯达克代码:NKTX-GET Rating)的股票评级从表现优于大盘下调至市场表现。
A number of other research analysts have also weighed in on NKTX. Cantor Fitzgerald reaffirmed an overweight rating on shares of Nkarta in a research note on Wednesday, September 21st. Canaccord Genuity Group began coverage on shares of Nkarta in a report on Monday, October 10th. They issued a buy rating and a $25.00 price objective on the stock. Mizuho lowered their price objective on shares of Nkarta from $81.00 to $26.00 and set a buy rating on the stock in a report on Wednesday, November 16th. Finally, Canaccord Genuity Group began coverage on shares of Nkarta in a report on Monday, October 10th. They issued a buy rating and a $25.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $29.90.
其他一些研究分析师也加入了对NKTX的看法。康托·菲茨杰拉德在9月21日星期三的一份研究报告中重申了对Nkarta股票的增持评级。Canaccel Genuity Group在10月10日星期一的一份报告中开始报道Nkarta的股票。他们对该股发布了买入评级和25.00美元的目标价。瑞穗在11月16日周三的一份报告中将Nkarta的股票目标价从81.00美元下调至26.00美元,并对该股设定了买入评级。最后,Canaccel Genuity Group在10月10日星期一的一份报告中开始报道Nkarta的股票。他们对该股发布了买入评级和25.00美元的目标价。一名股票研究分析师对该股的评级为持有,九名分析师对该公司股票的评级为买入。根据MarketBeat.com的数据,该公司目前的共识评级为适度买入,共识目标价为29.90美元。
Nkarta Stock Performance
Nkarta股票表现
Shares of NKTX opened at $5.54 on Thursday. Nkarta has a twelve month low of $5.22 and a twelve month high of $20.35. The firm's 50 day moving average price is $9.73 and its two-hundred day moving average price is $12.45. The firm has a market cap of $270.41 million, a P/E ratio of -2.07 and a beta of -0.06.
周四,NKTX的股价开盘报5.54美元。Nkarta的12个月低点为5.22美元,12个月高位为20.35美元。该公司的50日移动均线价格为9.73美元,200日移动均线价格为12.45美元。该公司市值为2.7041亿美元,市盈率为-2.07倍,贝塔系数为-0.06倍。
Insider Buying and Selling
内幕买卖
Hedge Funds Weigh In On Nkarta
对冲基金对Nkarta进行加码
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NKTX. Parkwood LLC bought a new stake in shares of Nkarta in the second quarter valued at about $31,000. Quantbot Technologies LP boosted its position in shares of Nkarta by 39.1% in the first quarter. Quantbot Technologies LP now owns 3,200 shares of the company's stock valued at $36,000 after acquiring an additional 900 shares during the period. Denali Advisors LLC bought a new stake in shares of Nkarta in the second quarter valued at about $38,000. Point72 Hong Kong Ltd bought a new stake in shares of Nkarta in the third quarter valued at about $46,000. Finally, Federated Hermes Inc. boosted its position in shares of Nkarta by 735.3% in the first quarter. Federated Hermes Inc. now owns 4,711 shares of the company's stock valued at $54,000 after acquiring an additional 4,147 shares during the period. 87.22% of the stock is owned by institutional investors.
许多对冲基金和其他机构投资者最近增持或减持了NKTX的股份。Parkwood LLC在第二季度购买了Nkarta的新股,价值约3.1万美元。Quantbot Technologies LP在第一季度将其在Nkarta股票的头寸提高了39.1%。Quantbot Technologies LP在此期间额外购买了900股,现在拥有3200股该公司的股票,价值3.6万美元。Denali Advisors LLC在第二季度购买了Nkarta的新股,价值约3.8万美元。Point72 Hong Kong Ltd在第三季度购买了Nkarta的新股,价值约4.6万美元。最后,联合爱马仕公司在第一季度将其持有的恩卡塔股票头寸提高了735.3%。联合爱马仕公司在此期间增持了4,147股,目前持有该公司4,711股股票,价值54,000美元。87.22%的股份由机构投资者持有。
About Nkarta
关于恩卡尔塔
(Get Rating)
(获取评级)
Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
Nkarta,Inc.是一家临床阶段的生物制药公司,开发和商业化癌症治疗的细胞疗法。该公司的细胞免疫疗法涉及自然杀伤(NK)细胞表面的嵌合抗原受体,使细胞能够识别肿瘤细胞表面存在的特定蛋白质或抗原。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Nkarta (NKTX)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- 免费获取StockNews.com关于NKTX的研究报告
- MarketBeat:回顾一周12/19-12/23
- 这些钢铁制造商理应在2023年观察名单上占有一席之地
- 通胀降温,标普500指数何去何从
- Cintas以经营杠杆击败通胀
- 你买下Palantir的决定可能只是个时间问题
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Nkarta Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Nkarta和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧